Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
761-780 of 1,782 trials

Diffuse Large B-cell Lymphoma: Loncastuximab and Epcoritamab Study

We are studying a combination of two medications for patients with relapsed or refractory diffuse large B-cell lymphoma. The goal is to see how well this treatment works and its safety compared to existing options.

Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL) Grade 3BHigh-Grade B-Cell Lymphoma (HGBL)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Liver Cirrhosis: Stopping Proton-Pump Inhibitors

We are studying whether stopping proton-pump inhibitors helps or harms patients with liver cirrhosis compared to those who continue the medication. This trial looks at hospitalizations, infections, and overall health outcomes.

Liver Cirrhosis1-2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsStandard MedicinesGastroenterologyInternal Medicine

Severe von Willebrand Disease: Vonicog Alfa Prophylaxis

We are studying whether vonicog alfa can help prevent bleeding episodes in children with severe von Willebrand disease. The trial will also look at the safety of this treatment over time.

Von Willebrand Disease1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematology

Non-Small Cell Lung Cancer: Osimertinib with Datopotamab Deruxtecan

We are studying the safety and effectiveness of combining osimertinib with datopotamab deruxtecan in patients with advanced non-small cell lung cancer that has an EGFR mutation. This trial aims to see if the combination works better than osimertinib alone.

Non-Squamous Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Stroke Treatment: Thrombolysis for Patients on Factor Xa Inhibitors

We are studying whether intravenous thrombolysis can improve recovery in stroke patients who have recently taken Factor Xa inhibitors. This trial compares the effects of this treatment to standard care options.

Acute Ischemic Stroke>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Mantle Cell Lymphoma: Zanubrutinib with Rituximab

We are comparing a new treatment combining Zanubrutinib and Rituximab to standard therapy for patients with untreated mantle cell lymphoma who cannot have a stem cell transplant. The goal is to see which treatment works better and is safer.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Difelikefalin for Itching in Adolescents on Hemodialysis

We are studying whether difelikefalin is safe for adolescents aged 12 to 17 who have moderate-to-severe itching related to long-term kidney disease. This trial aims to help improve care for young patients undergoing hemodialysis.

Generalized ItchingChronic Kidney Diseases3-6 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteDermatologyNephrologyPediatrics

Kidney Transplant: BIVV020 for Rejection Prevention and Treatment

We are studying BIVV020 to see if it can help prevent or treat antibody-mediated rejection in adults who have received a kidney transplant. This trial will assess its safety and how well it works compared to current treatments.

Transplant Rejection1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyInfectious DiseasesInternal MedicineOncology

Chemotherapy Dose Adjustment for DPD-Deficient Gastrointestinal Cancer Patients

We are studying how to safely adjust chemotherapy doses for patients with gastrointestinal cancers who lack a specific liver enzyme. This may help reduce severe side effects during treatment.

Gastrointestinal Cancer Patients Starting Chemotherapy>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Tranexamic Acid for Reducing Blood Transfusions in Abdominal Surgery

We are studying whether Tranexamic Acid can lower blood loss and the need for blood transfusions during major abdominal surgeries. This trial also examines safety and recovery outcomes for patients.

Intraoperative Bleeding1-2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesHematologyOrthopedics and Traumatology

Melanoma Treatment: Short vs. Long Immunotherapy

We are studying whether 6 months of immunotherapy after surgery is as effective as 12 months for patients with high-risk malignant melanoma. This could help determine the best treatment duration for better outcomes.

Skin Cancer (Melanoma)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesDermatologyOncology

Inebilizumab for Children with Neuromyelitis Optica Spectrum Disorder

We are studying how the medication inebilizumab affects children and adolescents with NMOSD. The trial will help us learn about its safety and how it impacts their health and daily life.

Neuromyelitis Optica Spectrum Disorder1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNeurology

Non-Functioning Pituitary Adenomas: Cabergoline Treatment

We are studying the effects of cabergoline on non-functioning pituitary adenomas. This trial aims to see if this medication can improve treatment outcomes for patients.

Non-functioning Pituitary Adenoma>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteEndocrinologyOncology

Bone Health: Alendronate Discontinuation Study

We are investigating the effects of stopping alendronate on fracture risk in patients with osteoporosis. The study also looks at whether specific health factors can predict bone loss after discontinuation.

Osteoporosis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementInternal MedicineOtolaryngology

Venous Malformations: Enalapril Study

We are testing the medication enalapril in adults with painful venous malformations to see if it helps reduce pain and improve quality of life. We will also look at any changes in the size of the malformations.

Venous Malformation>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineOrthopedics and Traumatology

Meniscal Pain Relief: Betamethasone Infiltration Study

We are testing whether ultrasound-guided betamethasone injections can reduce pain in adults with degenerative meniscal injuries. This study compares the treatment to a placebo to assess its effectiveness and safety.

Meniscal Pain3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteInternal MedicineOrthopedics and Traumatology

Tocilizumab for Painful Chronic Pancreatitis

We are studying whether tocilizumab can help reduce pain and improve quality of life for people with chronic pancreatitis. The trial will compare its effects to a placebo treatment.

Chronic Pancreatitis3-6 monthsEfficacy phase (II)Standard MedicinesGastroenterologyInternal Medicine

Stage IV Non-Small Cell Lung Cancer: Immunotherapy and Radiotherapy Study

We are exploring whether combining immunotherapy with extensive radiotherapy is safe and effective for patients with stage IV non-small cell lung cancer. This study will help us understand the treatment's impact on health and quality of life.

Non-small Cell Lung Cancer (Stage IV)>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology

Corneal Endothelial Transplantation: NSAIDs vs. Steroids

We are comparing two medication regimens to see if adding NSAIDs helps reduce inflammation and cystoid macular edema after corneal endothelial transplantation. This study is for patients undergoing this specific eye surgery.

Fuchs Dystrophy>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesOphthalmology

Breast Cancer: Personalized Treatment with Capivasertib

We are studying a new treatment combining capivasertib with letrozole for women with hormone receptor positive breast cancer. This trial aims to see if this approach improves survival compared to standard treatment.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyOncology